PMID- 32110650
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2297-4725 (Print)
IS  - 2297-475X (Electronic)
IS  - 2297-4725 (Linking)
VI  - 36
IP  - 1
DP  - 2020 Feb
TI  - Gender Differences in Multiple Endocrine Neoplasia Type 1: Implications for 
      Screening?
PG  - 3-9
LID - 10.1159/000505498 [doi]
AB  - BACKGROUND: Some gender-related differences have been reported in multiple 
      endocrine neoplasia type 1 (MEN1), although not all reports are conclusive. This 
      systematic review with analysis of the own MEN1 cohort evaluates gender 
      differences and potential consequences for screening. METHODS: A systematic 
      review of the literature between 1990 and 2019 with the search terms "MEN1" or 
      "multiple endocrine neoplasia type 1" and "gender" or "sex" was performed. In 
      addition, the prospectively collected data of a genetically confirmed MEN1 cohort 
      of the Philipps University Marburg were retrospectively analyzed. RESULTS: Review 
      of the literature identified five retrospective case series with original data of 
      1,057 MEN1 patients. One series suggested a higher frequency of pancreatic 
      neuroendocrine neoplasms (NEN), especially gastrinomas, in men (61 vs. 54%) and a 
      higher frequency of pituitary tumors in women (47 vs. 30%), but others did not. 
      Only thymic NEN occurred predominantly in men throughout all studies. Women with 
      MEN1 were found to have an increased risk of breast cancer. In the own series 
      consisting of 116 MEN1 patients (male = 58, female = 58), thymic lesions were 
      also more frequently detected in male patients (male = 5, female = 1). No gender 
      difference was found with regard to the other manifestations. CONCLUSION: 
      Regarding the typical MEN1 tumor manifestations, gender-adapted diagnostic and 
      therapeutic approaches cannot be recommended. Female MEN1 patients should be 
      encouraged to participate in breast cancer screening programs.
CI  - Copyright (c) 2020 by S. Karger AG, Basel.
FAU - Manoharan, Jerena
AU  - Manoharan J
AD  - Department of Visceral, Thoracic and Vascular Surgery, Philipps University 
      Marburg, Marburg, Germany.
FAU - Bollmann, Carmen
AU  - Bollmann C
AD  - Department of Visceral, Thoracic and Vascular Surgery, Philipps University 
      Marburg, Marburg, Germany.
FAU - Kann, Peter Herbert
AU  - Kann PH
AD  - Division of Endocrinology, Philipps University Marburg, Marburg, Germany.
FAU - Di Fazio, Pietro
AU  - Di Fazio P
AD  - Department of Visceral, Thoracic and Vascular Surgery, Philipps University 
      Marburg, Marburg, Germany.
FAU - Bartsch, Detlef K
AU  - Bartsch DK
AD  - Department of Visceral, Thoracic and Vascular Surgery, Philipps University 
      Marburg, Marburg, Germany.
FAU - Albers, Max B
AU  - Albers MB
AD  - Department of Visceral, Thoracic and Vascular Surgery, Philipps University 
      Marburg, Marburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200124
PL  - Switzerland
TA  - Visc Med
JT  - Visceral medicine
JID - 101681546
PMC - PMC7036590
OTO - NOTNLM
OT  - Gender
OT  - Multiple endocrine neoplasia type 1
OT  - Screening
COIS- The authors have nothing to disclose.
EDAT- 2020/02/29 06:00
MHDA- 2020/02/29 06:01
PMCR- 2021/02/01
CRDT- 2020/02/29 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2019/12/17 00:00 [accepted]
PHST- 2020/02/29 06:00 [entrez]
PHST- 2020/02/29 06:00 [pubmed]
PHST- 2020/02/29 06:01 [medline]
PHST- 2021/02/01 00:00 [pmc-release]
AID - vis-0036-0003 [pii]
AID - 10.1159/000505498 [doi]
PST - ppublish
SO  - Visc Med. 2020 Feb;36(1):3-9. doi: 10.1159/000505498. Epub 2020 Jan 24.